Boston Scientific (BSX) Ticks Higher Following FDA Approval of Stent System
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) shares are up in after-hours trading following reports it received U.S. FDA approval for its Epic Vascular Self-Expanding Stent System. Shares are about 4.6 percent higher.
For more color on the approval, click here.
For more color on the approval, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kailera reports positive Phase 3 data for oral obesity drug KAI-7535
- EU approves AbbVie's Tepkinly combo for follicular lymphoma
- Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
